Literature DB >> 20044048

Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices.

Sandra S Renteria1, Courtney C Clemens, Maria A Croyle.   

Abstract

A nasal adenovirus-based vaccine is under development. To determine if aggregation occurs during vaccination, infectious titer (limiting dilution) and capsid integrity (dynamic light scattering) were assessed after extrusion of a model vector from two intranasal delivery devices. Preparations of 2.5x10(12) and 1.25x10(11) virus particles (vp)/ml were studied. Virus aggregated ( approximately 10%) in the multi-dose vessel. Virus titer dropped by one log. Virus in the unit-dose device aggregated ( approximately 1%). Titer remained unchanged. Aggregation was concentration dependent. Formulations prevented aggregation during actuation, freeze-thaw and long-term storage. The device, formulation and dose may significantly influence aggregation and potency of any nasal adenovirus 5-based vaccine. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044048     DOI: 10.1016/j.vaccine.2009.12.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact.

Authors:  Kristina Jonsson-Schmunk; Maria A Croyle
Journal:  Expert Rev Anti Infect Ther       Date:  2015-03-23       Impact factor: 5.091

2.  Evaluation of nanoparticle tracking analysis for total virus particle determination.

Authors:  Petra Kramberger; Mateja Ciringer; Aleš Štrancar; Matjaž Peterka
Journal:  Virol J       Date:  2012-11-12       Impact factor: 4.099

3.  Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus.

Authors:  Qin Zeng; Jianfeng Han; Dong Zhao; Tao Gong; Zhirong Zhang; Xun Sun
Journal:  Int J Nanomedicine       Date:  2012-02-27

4.  Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2015-01-20       Impact factor: 4.939

5.  Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.

Authors:  Per Gisle Djupesland
Journal:  Drug Deliv Transl Res       Date:  2012-10-18       Impact factor: 4.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.